Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and
Market Forecasts to 2018
Published on November 2011

Report Summary

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Crohn's Disease (CD) Therapeutics - Pipeline Assessment
and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Crohn's Disease
Therapeutics market. The report identifies the key trends shaping and driving the global Crohn's Disease Therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the
market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products
within the global Crohn's Disease Therapeutics sector. This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global Crohn's disease (CD) therapeutics market to be worth at $3.6 billion in 2010. From 2005-2010, the
market grew at a compound annual growth rate (CAGR) of 25.2%, from $1.2 billion in 2005 to $3.6 billion in 2010. The high growth
rate during 2005-2010 is primarily attributed to the launches of the biologics such as Humira (adalimumab), Cimzia (certolizumab
pegol) and Tysabri (natalizumab) and increased uptake of Remicade (infliximab) and Entocort EC (budesonide). The CD therapeutics
market is forecast to show moderate growth at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This will come
as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars. The CD therapeutics
pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set generic
incursion and drive the market.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges for the CD therapeutics market. Its scope includes -
- Annualized information for the CD therapeutics market in seven key markets (the US, France, Germany, Italy, Spain, the UK and
Japan) with revenue data from 2005'2010 and forecasts to 2018.
- Pipeline analysis data which provides information on different phases, mechanisms of action being developed and emerging trends.
Pipeline candidates fall under major therapeutic classes such as interleukin inhibitors and enzyme inhibitors, stem cell therapy,
integrin antagonists, tumor necrosis inhibitors and immunomodulators.
- Analysis of current and future competition in the global CD therapeutics market. Key market companies covered are:
GlaxoSmithKline plc, Johnson & Johnson, Ocera Therapeutics, Inc., Osiris Therapeutics, Inc., Takeda Pharmaceutical Company
Limited, and Otsuka Pharmaceutical Co., Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the CD
therapeutics market.
- Analysis of key recent licensing and partnership agreements in the CD therapeutics market.

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and
through identification of companies with the strongest pipelines.
- Develop business strategies through understanding of the trends which shape and drive the global CD therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to
impact the global CD therapeutics market in the future.
- Formulate effective sales and marketing strategies through understanding of the competitive landscape and analysis of the
performance of various competitors.
- Identify emerging companies with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying market categories and segments that present the best opportunities for
consolidations, investments and strategic partnerships.
- What's the next big thing in the global CD therapeutics market landscape' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Crohn's Disease(CD) Therapeutics: Executive Summary 9
2.1 The CD Therapeutics Market is Forecast to Show Increased Growth until 2018 9
2.2 Competition in CD Therapeutics Market Becoming More Intense 10
2.3 The CD Therapeutics Market has Moderate Unmet Need 11
2.4 Emerging Therapies in Pipeline are Expected to Increase the Competition 12
3 Crohn's Disease(CD) Therapeutics: Introduction 14
3.1 Overview 14
3.2 Types of CD 14
3.3 Perianal CD 15
3.3.1 Classification of Perianal CD 15
3.4 CD Diagnosis and Classification based on Severity and Location 16
3.5 Epidemiology 17
3.6 Etiology 18
3.7 Signs and Symptoms 18
3.8 Extraintestinal Manifestations of CD 19
3.9 Diagnosis of CD 19
3.10 Pathophysiology 21
3.11 Treatment and Management Pattern 22
3.11.1 Medical or Pharmacological Management of CD 22
3.11.2 Surgical Management of CD 24
3.12 GlobalData Pipeline Report Guidance 25
4 Crohn's Disease (CD) Therapeutics: Market Characterization 26
4.1 CD Therapeutics Market Size (2005'2010) ' Global 26
4.2 CD Therapeutics Market Forecast (2010'2018) ' Global 28



4.3 CD Therapeutics Market Size (2005'2010) ' The US 30
4.4 CD Therapeutics Market Forecast (2010'2018) ' The US 31
4.5 CD Therapeutics Market Size (2005'2010) ' France 33
4.6 CD Therapeutics Market Forecast (2010'2018) ' France 34
4.7 CD Therapeutics Market Size (2005'2010) ' Germany 36
4.8 CD Therapeutics Market Forecast (2010'2018) ' Germany 37
4.9 CD Therapeutics Market Size (2005'2010) ' Italy 39
4.10 CD Therapeutics Market Forecast (2010'2018) ' Italy 40
4.11 CD Therapeutics Market Size (2005'2010) ' Spain 42
4.12 CD Therapeutics Market Forecast (2010'2018) ' Spain 43
4.13 CD Therapeutics Market Size (2005'2010) ' The UK 45
4.14 CD Therapeutics Market Forecast (2010'2018) ' The UK 46
4.15 CD Therapeutics Market Size (2005'2010) ' Japan 48
4.16 CD Therapeutics Market Forecast (2010'2018) ' Japan 49
4.17 Drivers and Barriers for the CD Therapeutics Market 51
4.17.1 Drivers for the CD Therapeutics Market 51
4.17.2 Barriers for the Crohn's Disease Market 52
4.18 Key Events Impacting the Future Market 52
4.19 Opportunity and Unmet Need 53
4.20 Key Takeaway 55
5 CD Therapeutics Market: Competitive Assessment 57
5.1 Overview 57
5.2 Strategic Competitor Assessment 57
5.3 Product Profile for the Major Marketed Products in the Crohn's Disease Therapeutics Market 58
5.3.1 Entocort EC (budenoside) 58
5.3.2 Humira (adalimumab) 59
5.3.3 Tysabri (natalizumab) 61
5.3.4 Remicade (infliximab) 62
5.3.5 Cimzia (cetrolizumab pegol) 64
5.4 Key Takeaway 66
6 CD Therapeutics Market: Pipeline Assessment 67
6.1 Overview 67
6.2 Strategic Pipeline Assessment 67
6.3 CD Therapeutics Pipeline Analysis ' Pipeline by Phases of Development 68
6.3.1 CD Therapeutics ' Phase III Pipeline 68
6.3.2 CD Therapeutics ' Phase II/III Pipeline 68
6.3.3 CD Therapeutics ' Phase II Pipeline 69
6.3.4 CD Therapeutics ' Phase I/II Pipeline 69
6.3.5 CD Therapeutics ' Phase I Pipeline 70
6.3.6 CD Therapeutics ' Preclinical Pipeline 70
6.3.7 CD Therapeutics ' Discovery Pipeline 70
6.4 CD Therapeutics- Clinical Pipeline by Mechanism of Action 71
6.5 CD Therapeutics-Technology Trends Analytical Framework 72
6.6 Crohn's Disease Therapeutics ' Promising Drugs with Novel mechanisms of action under Clinical Development 74
6.7 Molecule Profile for Late-stage Drugs under Clinical Development 76
6.7.1 Traficet-EN (CCX282) 76
6.7.2 Vedolizumab (MLN0002) 77
6.7.3 Prochymal 77



6.7.4 Stelara 78
6.8 Key Takeaway 79
7 Crohn's DiseaseTherapeutics ' Clinical Trials Mapping 81
7.1 Clinical Trials by Country (US, EU5 and Japan) 81
7.2 Clinical Trials by Phase 82
7.3 Clinical Trials by Trial Status 83
7.4 Overall Sponsors 84
7.5 Prominent Sponsor 85
7.6 Top Companies Participating in Therapeutics Clinical Trials, 2011 86
8 Crohn's DiseaseTherapeutics: Strategic Assessment 88
8.1 CD Therapeutics Market: Implications for Future Market Competition 88
9 Crohn's Disease Market: Future Players in the Crohn's Disease Market 90
9.1 Introduction 90
9.2 Company Profile 91
9.2.1 Centocor Ortho Biotech Inc 91
9.2.2 GlaxoSmithKline 91
9.2.3 Johnson & Johnson 93
9.2.4 Ocera Therapeutics, Inc. 95
9.2.5 Osiris Therapeutics, Inc. 95
9.2.6 Otsuka Pharmaceutical Co; Ltd (Subsidiary of Otsuka Holdings Co, Ltd.) 97
9.2.7 Takeda Pharmaceutical Company Limited 97
10 CD Therapeutics: Licensing and Partnership Deals 102
11 CD Therapeutics: Appendix 105
11.1 Definitions 105
11.2 Acronyms 105
11.3 Research Methodology 106
11.3.1 Coverage 106
11.3.2 Secondary Research 107
11.3.3 Forecasting 107
11.3.4 Primary Research 110
11.3.5 Expert Panel Validation 111
11.4 Contact Us 111
11.5 Disclaimer 111
11.6 Bibliography 112

List of Tables

Table 1: Definitions of CD Activity 20
Table 2: Estimated Prevalence of CD in Major Seven Key Market 20
Table 3: Extraintestinal Manifestations of CD 22
Table 4: CD Therapeutics Market, Global, Revenue ($bn), 2005'2010 30
Table 5: CD Therapeutics Market, Global, Forecast ($bn), 2010'2018 32
Table 6: CD Therapeutics Market, The US, Revenue ($bn), 2005'2010 34
Table 7: CD Therapeutics Market, The US, Forecast ($bn), 2010'2018 36
Table 8: CD Therapeutics Market, France, Revenue ($m), 2005'2010 37
Table 9: CD Therapeutics Market, France, Forecast ($m), 2010'2018 39
Table 10: CD Therapeutics Market, Germany, Revenue ($m), 2005'2010 40
Table 11: CD Therapeutics Market, Germany, Forecast ($m), 2010'2018 42



Table 12: CD Therapeutics Market, Italy, Revenue ($m), 2005'2010 43
Table 13: CD Therapeutics Market, Italy, Forecast ($m), 2010'2018 45
Table 14: CD Therapeutics Market, Spain, Revenue ($m), 2005'2010 46
Table 15: CD Therapeutics Market, Spain, Forecast ($m), 2010'2018 48
Table 16: CD Therapeutics Market, The UK, Revenue ($m), 2005'2010 49
Table 17: CD Therapeutics Market, The UK, Forecast ($m), 2010'2018 51
Table 18: CD Therapeutics Market, Japan, Revenue ($m), 2005'2010 52
Table 19: CD Therapeutics Market, Japan, Forecast ($m), 2010'2018 54
Table 20: CD Therapeutics ' Phase III Pipeline, 2011 71
Table 21: CD Therapeutics ' Phase II/III Pipeline, 2011 72
Table 22: CD Therapeutics ' Phase II Pipeline, 2011 72
Table 23: CD Therapeutics ' Phase I/II Pipeline, 2011 72
Table 24: CD Therapeutics ' Phase I Pipeline, 2011 73
Table 25: CD Therapeutics ' Preclinical Pipeline, 2011 73
Table 26: CD Therapeutics ' Discovery Pipeline, 2011 73
Table 27: CD Therapeutics - Mechanism of Action That Constitute Others in the Above Pie Chart 75
Table 28: Crohn's Disease Therapeutics ' Most Promising Drugs Under Clinical Development 77
Table 29: CD Therapeutics ' Clinical Trials by Country, 2011 85
Table 30: CD Therapeutics ' Clinical Trials by Phase, 2011 86
Table 31: CD Therapeutics ' Clinical Trials by Status, 2011 87
Table 32: CD Therapeutics ' Overall Sponsors, 2011 88
Table 33: CD Therapeutics ' Prominent Sponsors, 2011 89
Table 34: CD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 90
Table 35: GlaxoSmithKline (GSK) Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 96
Table 36: Johnson & Johnson (J&J) Autoimmune and Gastrointestinal Disease Pipeline Products, 2011 97
Table 37: Ocera Therapeutics, Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, 2011 98
Table 38: Osiris Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 100
Table 39: Takeda Pharmaceutical Company Limited Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 102
Table 40: Licensing and Partnership Deals 105

List of Figures

Figure 1: CD Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018 12
Figure 2: Opportunity and Unmet Need in the CD Therapeutics Market, 2010 15
Figure 2: CD Types 18
Figure 3: Pathophysiology of CD 24
Figure 4: Inflammatory CD Treatment Algorithm 26
Figure 5: Perianal CD Treatment Algorithm 27
Figure 6: CD Therapeutics Market, Global, Revenue ($bn), 2005'2010 29
Figure 7: CD Therapeutics, Market Share (%), 2010 31
Figure 8: CD Therapeutics Market, Global, Forecast ($bn), 2010'2018 32
Figure 9: CD Therapeutics, Market Share (%), 2018 33
Figure 10: CD Therapeutics Market, The US, Revenue ($bn), 2005'2010 34
Figure 11: CD Therapeutics Market, The US, Forecast ($bn), 2010'2018 35
Figure 12: CD Therapeutics Market, France, Revenue ($m), 2005'2010 36
Figure 13: CD Therapeutics Market, France, Forecast ($m), 2010'2018 38
Figure 14: CD Therapeutics Market, Germany , Revenue ($m), 2005'2010 39
Figure 15: CD Therapeutics Market, Germany , Forecast ($m), 2010'2018 41



Figure 16: CD Therapeutics Market, Italy, Revenue ($m), 2005'2010 42
Figure 17: CD Therapeutics Market, Italy, Forecast ($m), 2010'2018 44
Figure 18: CD Therapeutics Market, Spain, Revenue ($m), 2005'2010 45
Figure 19: CD Therapeutics Market, Spain, Forecast ($m), 2010'2018 47
Figure 20: CD Therapeutics Market, The UK, Revenue ($m), 2005'2010 48
Figure 21: CD Therapeutics Market, The UK, Forecast ($m), 2010'2018 50
Figure 22: CD Therapeutics Market, Japan, Revenue ($m), 2005'2010 51
Figure 23: CD Therapeutics Market, Japan, Forecast ($m), 2010'2018 53
Figure 24: CD Therapeutics, Key Events Impacting Future Market 56
Figure 25: Opportunity and Unmet Need in the Crohn's Disease Therapeutics Market,2010 57
Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Crohn's Disease,2010 61
Figure 27: CD Therapeutics Pipeline by Phase of Clinical Development, 2011 71
Figure 28: CD Therapeutics-Clinical Pipeline by Mechanism of Action 74
Figure 29: Technology Trends Analytical Framework of The CD Therapeutics Pipeline, 2011 76
Figure 30: Technology Trends Analytical Framework of The CD Therapeutics Pipeline - Description, 2011 77
Figure 31: CD Therapeutics ' Clinical Trials by Country, 2011 84
Figure 32: CD Therapeutics ' Clinical Trials by Phase, 2011 85
Figure 33: CD Therapeutics ' Clinical Trials by Status, 2011 86
Figure 34: CD Therapeutics ' Overall Sponsors, 2011 87
Figure 35: CD Therapeutics ' Prominent Sponsors, 2011 88
Figure 36:CD Therapeutics ' Top Companies Participating in Therapeutics Clinical Trials, 2011 90
Figure 37: Implications for Future Market Competition in the CD Therapeutics Market, 2010 91
Figure 38: CD Therapeutics Market, Clinical Pipeline by Company, June 2011 93
Figure 39: GlobalData Market Forecasting Model 112Centocor Ortho Biotech Inc
GlaxoSmithKline
Johnson & Johnson
Ocera Therapeutics, Inc.
Osiris Therapeutics, Inc.


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018